Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression
Completed · Not applicable · Has a placebo group
Conditions studied: Depressive Disorder, Major
In brief
The purpose of this study is to determine whether taking the medication memantine reduces impairment of memory and attention associated with electroconvulsive therapy.
Key facts
- Study ID
- NCT00186498
- Run by
- Stanford University
- People needed
- 11
- Starts
- 2004-02-01
- Expected to finish
- 2008-02-01
- Last updated by the study team
- 2019-09-27
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.